Johnson & Johnson (JNJ) transition underway, UBS assesses upcoming analyst day

Go back to Johnson & Johnson (JNJ) transition underway, UBS assesses upcoming analyst day

Johnson & Johnson (JNJ) slips as Laminar acquisition prompts a profit outlook cut

November 30, 2023 9:03 AM EST

Johnson & Johnson MedTech, the companys medical device business, announced today it finalized the acquisition of Laminar, a private medical device company specializing in addressing the left atrial appendage (LAA) in patients with non-valvular atrial fibrillation (AFib).

The acquisition involved an upfront payment of $400 million. Additionally, there are potential milestone payments related to... More

Johnson & Johnson MedTech (JNJ) Acquires Laminar, Inc. for $400 Million Plus Milestone Payments

November 30, 2023 8:41 AM EST

Johnson & Johnson MedTech1 today announced the completion of the acquisition2 of Laminar, Inc., a privately-held medical device company focused on eliminating the left atrial appendage (LAA) in patients with non-valvular atrial fibrillation (AFib). Johnson & Johnson MedTech acquired Laminar for an upfront payment of $400 million, subject to customary adjustments, with additional potential clinical and regulatory milestone payments in 2024 and beyond. Laminar joins Johnson & Johnson MedTech as part of Biosense Webster, Inc. a global leader in cardiac arrhythmia treatment.

Today, approximately 38 million patients around the world are living with AFib, which causes them to be more than five... More